Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Potential Interactions Between Intravenous Cocaine and Oral SXC-2023

NCT06343532 is registered in ClinicalTrials.gov with National Institute on Drug Abuse (NIDA) as lead sponsor.

NCT NCT06343532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06343532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Potential Interactions Between Intravenous Cocaine and Oral SXC-2023
Lead sponsor
National Institute on Drug Abuse (NIDA)
Phase
Phase 1
Overall status
Completed
Start date
October 8, 2024
Completion date
December 30, 2024
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cocaine use disorder